BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the 'Offering') of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock.

波士顿，2026年9月29日（环球电讯社）——Pyxis Oncology, Inc.（纳斯达克股票代码：PYXS）是一家处于临床阶段、致力于开发针对难治性癌症的下一代疗法的公司，今日宣布已启动一项注册公开发行（以下简称“本次发行”），内容包括：(i) 其普通股股份，或向特定投资者替代普通股发行用于购买普通股股份的预注资认股权证；以及 (ii) 附带的用于购买普通股股份的普通认股权证。

Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock..

每股普通股及每份预融资权证将与一份用于购买一股普通股的普通股认股权证一并出售。

The common warrants will become exercisable only upon approval by the Company's stockholders of an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the 'Charter Amendment Effective Date'), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later (x) of the Charter Amendment Effective Date and (y) the Company's public disclosure of overall survival data (the 'OS Data Release Date') from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), expected in the first half of 2027.

普通权证仅在公司股东批准对公司注册证书进行修订以增加授权普通股数量，且该修订生效（该生效日期为“章程修订生效日”）后方可行使，并将于以下较早日期到期：(i) 章程修订生效日的五周年纪念日；以及 (ii) 下列较晚日期之后的第30个日历日：(x) 章程修订生效日，以及 (y) 公司公开披露其正在进行的关于micvotabart pelidotin（MICVO）作为单药疗法用于二线及以后（2L+）复发/转移性头颈部鳞状细胞癌（R/M HNSCC）的1期临床试验的总生存期数据（该披露日期为“OS数据发布日期”），预计该数据将于2027年上半年公布。

All of the securities in the Offering are to be sold by Pyxis Oncology..

本次发行中的所有证券均由Pyxis Oncology出售。

Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the proposed Offering. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering..

Leerink Partners、Guggenheim Securities 和 Wells Fargo Securities 担任拟议发行的联合账簿管理人。拟议发行受市场及其他条件制约，无法保证发行是否或何时能够完成，也无法保证发行的实际规模或条款。

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes.

Pyxis Oncology 计划将本次发行所得净收益用于推进其领先临床项目 MICVO，以实现关键临床里程碑，包括针对二线及以上复发或转移性头颈部鳞状细胞癌（2L+ R/M HNSCC）的 planned Headliner™ III 期临床试验，并用于营运资金及一般公司用途。

The common stock, common warrants and pre-funded warrants are being offered pursuant to a registration statement on Form S-3 (File No. 333-291801), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the 'SEC'). The Offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.

普通股、普通认股权证及预付资金认股权证正依据S-3表格注册声明（文件编号：333-291801）进行发售，该注册声明此前已提交至美国证券交易委员会（“SEC”），并随后被宣布生效。本次发售仅通过构成注册声明一部分的招股说明书补充文件及随附招股说明书进行。

A copy of the preliminary prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available for free on the SEC's website at .

与本次发行相关并描述其条款的初步招股说明书补充文件的副本将提交给美国证券交易委员会（SEC），并可在美国证券交易委员会网站免费获取。

www.sec.gov

www.sec.gov

. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com..

初步招股说明书补充文件及随附的招股说明书的副本，在可获得的情况下，也可从以下机构获取：Leerink Partners LLC（收件人：银团部，地址：53 State Street, 40th Floor, Boston, MA 02109），电话：1-800-808-7525 转 6105，电子邮件：syndicate@leerink.com；Guggenheim Securities, LLC（收件人：股票银团部，地址：330 Madison Avenue, 8th Floor, New York, NY 10017），电话：(212) 518-9544，电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com；或 Wells Fargo Securities, LLC（收件人：股票银团部，地址：90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402），电话：(800) 645-3751（选项 #5），或通过电子邮件将请求发送至 WFScustomerservice@wellsfargo.com。

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或征求购买本次发行证券的要约，在任何州或其他司法管辖区，在根据该州或其他司法管辖区的证券法进行注册或资格认定之前，若此类要约、征求或销售属违法，则不得在这些地区销售上述证券。

About Pyxis Oncology

关于 Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM).

Pyxis Oncology, Inc. 是一家处于临床阶段的生物制药公司，致力于开发针对难治性癌症的治疗药物。公司的主要候选药物 micvotabart pelidotin（MICVO）是一款首创概念的抗体药物偶联物（ADC），靶向纤连蛋白的 B 外结构域（EDB+FN），这是肿瘤细胞外基质（ECM）的一种非细胞结构成分。

EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death.

EDB+FN在多种实体瘤的肿瘤微环境中选择性过表达，而在正常成人组织中基本缺失。MICVO旨在通过三重作用机制治疗实体瘤：直接杀伤癌细胞、旁观者效应以及免疫原性细胞死亡。

MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors.

MICVO 正在一项针对复发或转移性头颈部鳞状细胞癌（R/M HNSCC）患者的 1 期临床试验中作为单药疗法进行评估，并在另一项针对 R/M HNSCC 及其他实体瘤患者的 1/2 期临床试验中与默沙东的抗 PD-1 疗法 KEYTRUDA®（帕博利珠单抗）联合进行评估。

Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment..

Pyxis Oncology 致力于推进 MICVO 的研发，旨在改善复发或转移性头颈部鳞状细胞癌（R/M HNSCC）患者的预后，并为癌症治疗的实质性进展做出贡献。

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KEYTRUDA® 是默沙东有限责任公司（Merck Sharp & Dohme LLC）的注册商标，该公司为美国新泽西州拉威市默克公司（Merck & Co., Inc.）的子公司。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the anticipated Offering, including its timing, size, terms and completion and the anticipated gross proceeds therefrom (including from any exercise of the common warrants); the Company's ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company's intended use of the net proceeds from the Offering; the Company's plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company's ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements.

本新闻稿包含根据1995年《私人证券诉讼改革法》及其他联邦证券法律的安全港条款所界定的前瞻性陈述。除本新闻稿中包含的历史事实陈述外，所有其他陈述均为前瞻性陈述，包括但不限于以下方面的陈述：拟议的发行（包括其时间、规模、条款和完成情况及由此产生的预期总收益，包括行使普通权证所产生的收益）；公司获得股东批准并实施对其公司章程修正案的能力，该修正案为使普通权证可行使所必需，以及相关时间安排；OS数据发布日期的时间安排，该日期将影响普通权证的可行使期间；公司对发行净收益的预期用途；公司开发、生产和商业化MICVO的计划；公司正在进行的临床试验的时间安排和进展及其预期结果；管理层的计划和目标；以及公司未来的经营业绩和财务状况。

These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company's ability to complete the Offering on the anticipated terms, or at all; the Company's ability to.

这些陈述既非承诺也非保证，而是涉及已知和未知的风险、不确定性以及其他重要因素的陈述，其中某些因素是公司无法控制的，可能导致实际结果、业绩或成就与前瞻性陈述中明示或暗示的任何未来结果、业绩或成就存在重大差异，包括但不限于以下因素：市场及其他条件，以及公司能否按预期条款完成发行，或能否根本完成发行；公司的能力。

Pyxis Oncology Contact:

Pyxis Oncology 联系方式：

IR@pyxisoncology.com

IR@pyxisoncology.com